Mechanistic Pathophysiology & Research Targets
Diabetic Peripheral Neuropathy (DPN) results from chronic hyperglycemia-induced sorbitol accumulation, microvascular endoneurial ischemia (damage to the vasa nervorum), and chronic Schwann cell neuroinflammation.
Investigational protocols explore autologous bone marrow-derived mononuclear cells (BM-MNCs) or allogeneic human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) to evaluate three target biological axes:
Paracrine Angiogenesis
Paracrine Angiogenesis: Secretion of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) to evaluate restorative perfusion in micro-capillaries supplying peripheral nerve trunks.
Immunomodulatory Signaling
Immunomodulatory Signaling: Suppression of pro-inflammatory cascades (TNF-α, IL-6, NF-κB) to address persistent neuro-inflammatory pain transmission.
Axonal Protection
Axonal Microenvironment Protection: Secretion of neurotrophic factors (GDNF, BDNF) to preserve demyelinating Schwann cells from progressive oxidative injury.
Candidate Eligibility Criteria
Inclusion guidelines and clinical exclusions for peripheral nerve cellular therapy
Who May Qualify:
- • Adults (18–75 years) with confirmed Diabetic Peripheral Neuropathy (DPN) refractory to standard pharmacological care (e.g., gabapentinoids, SNRIs).
- • Documented residual nerve conduction velocity (NCV) or monofilament sensitivity loss.
- • Stable glycemic control with HbA1c typically ≤ 9.5%.
Contraindications (Exclusion):
- • Severe critical limb ischemia or active, unmanaged gangrenous foot ulcers requiring emergency surgical revascularization.
- • History of active malignancy or cancer remission < 5 years.
- • Complete, irreversible end-stage motor loss, active systemic sepsis, or severe coagulopathy.
Clinical Observations, Known Risks & Monitored Endpoints
Investigational Scope:
Cell-based therapy is not a definitive cure and does not replace glycemic control or medical diabetes management. Observed responses vary widely depending on disease chronicity, baseline microvascular patency, and strict metabolic adherence.
Reported Clinical Responses (Monitored Phase I/II Cohorts):
Neuropathic Pain Index
Neuropathic Pain Index: Partial score reduction on Visual Analog Scales (VAS) and Michigan Neuropathy Screening Instrument (MNSI) at 3- to 6-month follow-up.
Micro-Sensation
Micro-Sensation: Gradual subjective improvement in monofilament tactile perception and warm/cold discrimination in select non-end-stage cases.
Wound Microenvironment
Wound Microenvironment: Enhanced granulation in non-gangrenous, superficial plantar ulcers when combined with standard wound offloading and podiatric care.
Potential Risks, Adverse Events & Limitations:
• Transient Procedural Risks: Localized pain, hematoma, or infection at marrow aspiration/injection sites; transient fever or self-limiting headache post-infusion.
• Metabolic Reactions: Temporary glycemic fluctuations post-procedure requiring hourly insulin titration.
• Uncertain Longevity: Regenerative paracrine effects may diminish after 12–18 months, requiring continued conventional maintenance.
• Non-Response: A documented subset of patients exhibits zero symptomatic or neurophysiological improvement.
WHY CHOOSE OUR CENTER IN INDIA
State-of-the-art neurology infrastructure, rigorous batch testing, and transparent pricing
Hospital Accreditations
Hospital Accreditations: In-hospital stays and infusions are restricted to JCI (Joint Commission International) and NABH (National Accreditation Board for Hospitals) tertiary centers.
Laboratory Validation
Laboratory Validation: Cleanroom facilities maintain ISO 14644 Class 5 certification with third-party flow cytometry batch-release assays.
Transparent Pricing Structure:
Full Inpatient Investigative Protocol: $5,500 – $7,500 USD
Inclusions: Pre-procedure diagnostics (NCV, Doppler, metabolic labs), cell isolation/processing, 4 nights inpatient hospital accommodation, specialist consulting fees, local private transfers, and 12-month remote follow-up.
Exclusions: International flights, elective non-protocol procedures, extended ICU stays for unrelated acute complications.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted interventional or systemic cellular therapy based on severity).
(Aimed at reducing glycemic variability, stabilizing HbA1c, and protecting vital end-organ microvasculature).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | $5,500 – $8,500 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $50,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $45,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $20,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
SPECIAL SERVICES FOR INTERNATIONAL PATIENTS
Dedicated support services for international travelers managing mobility challenges
Tele-Triage
Complimentary Tele-Triage: Pre-travel review of your medical reports, NCV studies, and blood panels by our senior specialists within 48 hours.
Medical Visa Support
Medical Visa (MED Visa) Support: Official visa invitation letters and comprehensive liaison with the Indian Embassy/Consulate in your country.
Language Interpreters
Dedicated Language Interpreters: Full-time medical coordinators fluent in English, Arabic, Russian, and French.
12-Month Remote Co-Care
12-Month Remote Co-Care: Telehealth checkpoints scheduled at 1, 3, 6, and 12 months, coordinating directly with your hometown primary care physician.
LOGISTICS & ACCOMMODATION
Smooth transit, companion support, and wheelchair-accessible stays
Airport Transfers
Airport Transfers: 24/7 designated airport pickup and drop-off with private vehicle or medical transport from DEL, BOM, or BLR airports.
Hospital & Hotel Lodging
In-Hospital & Hotel Lodging: Private ensuite hospital rooms featuring attendant bedding; discounted negotiated rates at adjacent 4- and 5-star partner hotels.
Travel Concierge
Travel Concierge: On-site assistance with local SIM registration, foreign currency exchange, and customized dietary arrangements (Halal, diabetic-compliant, vegetarian).
5-DAY INTERNATIONAL TREATMENT SCHEDULE
Day-by-day clinical milestones during your inpatient stay in India
Day 1: Arrival & Baseline Evaluation
Chauffeur pickup from the airport, hospital admission, and baseline diagnostic workup (electromyography [EMG/NCV], glycemic profile, renal/hepatic panels).
Day 2: Multidisciplinary Clinical Triage
Comprehensive physical and neurological examination with the lead neurologist, endocrinologist, and regenerative specialist.
Day 3: Targeted Cell Administration
Cellular micro-infusion (systemic IV and/or targeted regional intramuscular/perivascular perfusion) administered under sterile ISO Class 5 cleanroom conditions.
Day 4: Monitoring & Adjuvant Protocols
24-hour vitals and glucose monitoring, adjuvant Hyperbaric Oxygen Therapy (HBOT) session, and diabetic podiatry assessment.
Day 5: Discharge & Departure
Review of post-procedure instructions, delivery of the 12-month remote monitoring manual, and private transfer to the airport.
Cellular Safety, Sterility & Procedural Governance
ISO Class 5 certified cleanrooms, flow cytometry validation, and rigorous safety monitoring
cGMP Cleanroom Processing
Processed under ISO Class 5 laminar flow biosafety hoods with continuous environmental monitoring.
Flow Cytometry Verification
ISCT criteria verified: ≥95% positive CD73/CD90/CD105 and ≤2% negative CD34/CD45/HLA-DR.
14-Day Sterility Testing
Automated multi-pathogen sterility cultures, mycoplasma PCR, and LAL endotoxin testing prior to use.
Ethics Committee Governance
All procedures adhere to CDSCO-registered Institutional Ethics Committee (IEC) oversight.
Frequently Asked Questions: Diabetic Neuropathy Care
Evidence-based clinical guidance regarding cellular therapy protocols, glycemic outcomes, and travel
Stem cells release potent pro-angiogenic factors (VEGF, bFGF) to re-establish blood flow through the occluded vasa nervorum microvessels supplying the nerve trunk. Simultaneously, neurotrophic factors (NGF, BDNF) stimulate axonal sprouting and remyelination by Schwann cells (Han et al., 2016).
Yes. By addressing the underlying nerve ischemia rather than merely numbing symptoms like standard painkillers (e.g. gabapentin or pregabalin), clinical trials report significant reductions in neuropathic pain and restoration of protective tactile sensation.
Yes. By improving microvascular perfusion and sensory perception in the lower extremities, patients regain protective sensation, significantly reducing ulcer formation risks and tissue necrosis.
Outcomes are verified through Nerve Conduction Velocity (NCV) electromyography, 10g Semmes-Weinstein monofilament tests, vibration perception thresholds (VPT), and visual analog pain scales (VAS).
Administration combines systemic intravenous infusion (for microvascular anti-inflammatory modulation) with precision ultrasound-guided intramuscular micro-injections along the pathways of the peroneal and tibial nerves.
The complete care pathway takes 3 to 4 days, accommodating baseline electrodiagnostic NCV scans, cellular administration, post-procedure assessment, and discharge with follow-up protocols.
Peer-Reviewed Scientific Citations & Clinical References
Key published clinical trials and peer-reviewed literature supporting cellular therapy in Diabetic Neuropathy:
MEDICAL DISCLAIMER & REGULATORY NOTICE
Investigational Status
Investigational Status: Stem cell therapy for Diabetic Neuropathy is an investigational, supportive modality under Indian Council of Medical Research (ICMR) and Institutional Ethics Committee (IEC) oversight. It is not an FDA-, EMA-, or CDSCO-approved cure, and complete reversal of nerve damage cannot be guaranteed.
Prescription Adherence
Prescription Adherence: Patients must continue their prescribed diabetes medications and analgesic regimens; any dosage changes must be authorized exclusively by the treating doctor.
Transparency Commitment
Transparency Commitment: Candidate suitability is determined strictly on individual medical records, duration of diabetes, and current neurological baseline.